Tests cizutamig in adults with hard-to-treat rheumatoid arthritis
Tests cizutamig for safety and early effects in adults with hard-to-treat rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis
Key facts
- Where
- Wuhan, ChinaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06946199, who can take part
Where in China
- Wuhan Union HospitalWuhan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Trial code
- NCT06946199
- Record updated
- 12 January 2026
- Original description
The purpose of the study is to evaluate the safety and efficacy of BCMAxCD3 T-cell engager (cizutamig) in patients with refractory seropositive RA.Read full original descriptionShow less
An Open-label Study Evaluating the Safety and Preliminary Clinical Activity of Cizutamig in Patients With Refractory Seropositive Rheumatoid Arthritis
The purpose of the study is to evaluate the safety and efficacy of BCMAxCD3 T-cell engager (cizutamig) in patients with refractory seropositive RA.
Inclusion: 18 to 75 years old at the time of signing the informed consent form; Diagnosis of adult-onset RA as defined by the 2010 ACR/EULAR classification criteria; Moderately to severely active RA; Positive test results for RF and/or ACPA at Screening; Inadequate treatment response defined as either lack of clinical benefit or intolerability to treatment with tsDMARD and/or bDMARD Exclusion Criteria:; Inadequate clinical laboratory parameters at Screening; Patients with active infection; Receipt of live vaccine within 4 weeks prior to Screening; Presence of any concomitant autoimmune disease; History of progressive multifocal leukoencephalopathy; History of primary immunodeficiency or a hereditary deficiency of the complement system; Central nervous system disease; Presence of 1 or more significant concurrent medical conditions per investigator judgment; Have a diagnosis or history of malignant disease within 5 years; Serious mental illness, alcohol or drug abuse, dementia, or any other condition that would impair the patient's ability to receive the planned treatment or to understand informed consent at the study site as determined by local practice.